Side effect-free cathepsin K targeting drugs for skeletal diseases

用于骨骼疾病的无副作用组织蛋白酶 K 靶向药物

• 批准号: 523434-2018
• 负责人: Bromme, Dieter
• 金额: $ 17.34万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=694653
• 关键词: Side; effect; free; cathepsin; targeting

Arthritic diseases affect 15 % of the population and bone cancer is a frequent metastatic sideeffect of the most common breast and prostate cancer. Aside from human suffering enormousfinancial health care costs are added to the treatment of these diseases. Current treatmentshave various shortcomings and side effects, which include increased cancer risks, atypicalfractures, bone necrosis, infections, and vascular problems. There is clearly a need for moreeffective and safer treatments. Unfortunately, little progress has been made in recent years.Most treatments attack rather non-specifically entire cells or block complex pathways, whichis likely causing the side effects. In contrast, the protease, cathepsin K, is solely responsiblefor the bone degradation and significantly contributes to joint erosion. Its inhibition has beenshown to effectively reduce fracture rates in post-menopausal women. However, thistreatment also had severe side effects leading to the termination of the further development ofcathepsin K inhibitors. Our research has identified and verified a novel type of cathepsin Kinhibitors without causing any of the side effects seen in clinical trials. Interestingly, a majorsource of these compounds are certain Chinese herbs traditionally used in skeletal diseases.Recently, we have shown the efficacy of one of these compounds in an osteoporosis modelwithout any observable side effects. This project will expand this approach and will generatemore potent and druggable derivatives from the herbal compounds. Compounds will beanalyzed in arthritis and bone cancer mouse models. We anticipate that these compounds willhave a superior efficacy with no or fewer side effects than current treatment regimes. Thisproject requires a strong interdisciplinary collaboration between chemists, pharmaceuticalscientists, biochemists, and animal model researchers and will provide an excellentopportunity for the training of students.

关节炎疾病影响了15%的人口，骨癌是最常见的乳腺癌和前列腺癌的常见转移性副作用。除了人类的痛苦之外，这些疾病的治疗还增加了巨大的财政保健费用。目前的治疗方法有各种缺点和副作用，包括增加癌症风险、非典型骨折、骨坏死、感染和血管问题。显然需要更有效和更安全的治疗方法。不幸的是，近年来进展甚微。大多数治疗方法攻击非特异性的整个细胞或阻断复杂的途径，这可能导致副作用。相反，蛋白酶组织蛋白酶K是骨降解的唯一原因，并对关节侵蚀起着重要作用。它的抑制已被证明可以有效地降低绝经后妇女的骨折率。然而，这种治疗也有严重的副作用，导致组织蛋白酶K抑制剂的进一步发展终止。我们的研究已经确定并验证了一种新型的组织蛋白酶激酶抑制剂，而不会引起临床试验中出现的任何副作用。有趣的是，这些化合物的主要来源是某些传统上用于治疗骨骼疾病的中草药。最近，我们在骨质疏松模型中显示了其中一种化合物的疗效，没有任何可观察到的副作用。该项目将扩展这种方法，并将从草药化合物中产生更有效和可用药的衍生物。化合物将在关节炎和骨癌小鼠模型中进行分析。我们预计这些化合物将比目前的治疗方案具有更好的疗效，没有或更少的副作用。该项目需要化学家、制药科学家、生物化学家和动物模型研究人员之间强有力的跨学科合作，并将为培养学生提供极好的机会。